Brind.

Abbott expanded access to bone disease treatment following regulatory approvals and portfolio expansion in Malaysia.

1 report, 1 independent Updated Aug 26

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Abbott Japan Malaysia

Keep exploring

The entities involved

Abbott Japan
Nothing else this week.
Malaysia
country in Southeast Asia
- Geographical facts confirm that Kuala Lumpur is the capital of Malaysia and Peninsular Malaysia is a portion of Malaysia.Mon 17:20
- MIFF is based in Kuala Lumpur.Mon 12:03

Related events

CytoMed Therapeutics Limited is targeting markets in Malaysia and Singapore.Sep 3

Coverage

Newest first; wire copies grouped

Aug 26PR NewswireAbbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment Abbott's denosumab biosimilar is the first approved in Thailand, making